JP Morgan Chase’s Trillium Therapeutics Inc. TRIL Stock Holding History

JP Morgan Chase’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,510,226	Closed	-$26.5M	–	7268
2021 Q3	$26.5M	Buy	1,510,226 +1,472,671	+3,921%	+$17.2M	﹤0.01%	1558
2021 Q2	$364K	Buy	+37,555	New	+$353K	﹤0.01%	4895
2020 Q2	–	Sell	-251,272	Closed	-$1.01M	–	5851
2020 Q1	$1.01M	Buy	+251,272	New	+$950K	﹤0.01%	3385
2018 Q3	–	Sell	-5,125	Closed	-$31K	–	5910
2018 Q2	$31K	Sell	5,125 -168	-3%	-$1.07K	﹤0.01%	5228
2018 Q1	$38K	Buy	+5,293	New	+$40.1K	﹤0.01%	4907
2017 Q1	–	Sell	-4,800	Closed	-$27K	–	5312
2016 Q4	$27K	Buy	+4,800	New	+$47.8K	﹤0.01%	4655
2016 Q2	–	Sell	-3,505	Closed	-$32K	–	5056
2016 Q1	$32K	Buy	+3,505	New	+$29.6K	﹤0.01%	3999

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

JP Morgan Chase's TRIL Position: Q4 2021 in Review

JP Morgan Chase sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 1,510,226 shares — an estimated $26.5M sold.

JP Morgan Chase first reported a position in TRIL in Q1 2016 and held it in 7 quarters. The position peaked at $26.5M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

JP Morgan Chase reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
JP Morgan Chase sold 1,510,226 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $26.5M.
JP Morgan Chase first reported a position in Trillium Therapeutics Inc. in Q1 2016 and held it in 7 quarters.
JP Morgan Chase's Trillium Therapeutics Inc. position peaked at $26.5M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on JP Morgan Chase's 13F filing for Q4 2021, filed 10 Feb 2022.